/
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
Revenue grew 43.7%, still solid.
Net debt of $147M represents 5.1x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$315M
▲ +43.7% YoY
Net Income (TTM)
$12M
▲ +101.0% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
$49M
▲ +177.4% YoY
Op. Cash Flow (TTM)
$49M
▲ +177.4% YoY
Net Debt
$147M
Cash & Equiv.
$112M
5Y CAGR: +70.2%
Continue Research